Secondary Logo

Journal Logo

April 2019 - Volume 30 - Issue 4
pp: 323-434


A randomized phase II study to determine the efficacy and tolerability of two doses of eribulin plus lapatinib in trastuzumab-pretreated patients with HER-2-positive metastatic breast cancer (E-VITA)

Bischoff, Joachim; Barinoff, Jana; Mundhenke, Christoph; More

Anti-Cancer Drugs. 30(4):394-401, April 2019.